Abstract
Polymyositis and dermatomyositis (PM-DM) are forms of idiopathic inflammatory myositis. Interstitial lung disease (ILD) in PM-DM is recognized as a serious complication and a major cause of death in this disease. According to the results of immunophenotyping of lymphocytes in bronchoalveolar lavage fluid, cytotoxic T lymphocytes may be major pulmonary inflammatory cells of ILD in PM-DM. Glucocorticoids are considered the first-line drug treatment for PMDM patients with ILD, however they are often not sufficient to obtain improvement of ILD as a single agent. Furthermore, the addition of immunosuppressive drugs becomes necessary as steroid sparing agents to avoid the severe sideeffects often seen with high-dose steroid treatment. Cyclophosphamide, cyclosporin, and tacrolimus were reported to be effective in treatment of refractory ILD in PM-DM. Although other immunosuppressive agents; mycophenolate mofetil, intravenous immunoglobulin, and anti-TNF agents have appeared as promising agents for refractory PM-DM, the efficacy on ILD in PM-DM is still unknown. Even if treatment is initiated early in the course of the disease, some patients still develop irreversible fatal lung fibrosis under aggressive immunosuppressive therapy. The fastest way to find the most effective treatment may be to investigate the pathogenesis of the disease in detail before initiation of immunosuppressive therapy including glucocorticoids.
Keywords: Polymyositis, dermatomyositis, amyopathic dermatomyositis, interstitial lung disease, cyclosporin, tacrolimus
Current Respiratory Medicine Reviews
Title: Interstitial Lung Disease Associated with Polymyositis-Dermatomyositis
Volume: 3 Issue: 3
Author(s): Toshinori Takada, Jun-ichi Narita, Eiichi Suzuki and Fumitake Gejyo
Affiliation:
Keywords: Polymyositis, dermatomyositis, amyopathic dermatomyositis, interstitial lung disease, cyclosporin, tacrolimus
Abstract: Polymyositis and dermatomyositis (PM-DM) are forms of idiopathic inflammatory myositis. Interstitial lung disease (ILD) in PM-DM is recognized as a serious complication and a major cause of death in this disease. According to the results of immunophenotyping of lymphocytes in bronchoalveolar lavage fluid, cytotoxic T lymphocytes may be major pulmonary inflammatory cells of ILD in PM-DM. Glucocorticoids are considered the first-line drug treatment for PMDM patients with ILD, however they are often not sufficient to obtain improvement of ILD as a single agent. Furthermore, the addition of immunosuppressive drugs becomes necessary as steroid sparing agents to avoid the severe sideeffects often seen with high-dose steroid treatment. Cyclophosphamide, cyclosporin, and tacrolimus were reported to be effective in treatment of refractory ILD in PM-DM. Although other immunosuppressive agents; mycophenolate mofetil, intravenous immunoglobulin, and anti-TNF agents have appeared as promising agents for refractory PM-DM, the efficacy on ILD in PM-DM is still unknown. Even if treatment is initiated early in the course of the disease, some patients still develop irreversible fatal lung fibrosis under aggressive immunosuppressive therapy. The fastest way to find the most effective treatment may be to investigate the pathogenesis of the disease in detail before initiation of immunosuppressive therapy including glucocorticoids.
Export Options
About this article
Cite this article as:
Toshinori Takada , Jun-ichi Narita , Eiichi Suzuki and Fumitake Gejyo , Interstitial Lung Disease Associated with Polymyositis-Dermatomyositis, Current Respiratory Medicine Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339807781387508
DOI https://dx.doi.org/10.2174/157339807781387508 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): Still an Obscure Disease
Central Nervous System Agents in Medicinal Chemistry Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD)
Current Respiratory Medicine Reviews The Possibilities and Pitfalls for Anti-Complement Therapies in Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Autoimmune Neuromuscular Disorders
Current Neuropharmacology Review of Pediatric Osteoarticular Infections
Reviews on Recent Clinical Trials Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease
Current Pharmaceutical Biotechnology Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma
Current Drug Safety Anti-inflammatory Effect of Predimenol, A Bioactive Extract from <i>Phaleria macrocarpa</i>, through the Suppression of NF-κB and COX-2
Recent Advances in Inflammation & Allergy Drug Discovery Association of flavonoid-rich foods and statins in the management of hypercholesterolemia: a dangerous or helpful combination?
Current Drug Metabolism Microbial Agents – Parasites
Current Rheumatology Reviews Hepatic Manifestations in Juvenile Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery Intravenous Immunoglobulin Preparations and Autoimmune Disorders: Mechanisms of Action
Current Pharmaceutical Biotechnology Bench to Bedside of CTLA-4: A Novel Immuno-Therapeutic Agent for Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Bidirectional Nature of Cardiovascular and Kidney Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design γ-Secretase-Regulated Signaling: Notch, APP, and Alzheimers Disease
Current Psychopharmacology Role of Free Radicals and Antioxidant Signaling in Skeletal Muscle Health and Pathology
Infectious Disorders - Drug Targets Subject Index to Volume 1
Current Alzheimer Research